Europe - Euronext Paris - EPA:ALNFL - FR0014003XT0 - Common Stock
The current stock price of ALNFL.PA is 1.17 EUR. In the past month the price increased by 27.73%. In the past year, price decreased by -36.76%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 68.21 | 44.30B | ||
| ARGX.BR | ARGENX SE | 68.11 | 44.24B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 18.82B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.50B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.31B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.84B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.84B | ||
| NANO.PA | NANOBIOTIX | N/A | 950.81M | ||
| 5CV.DE | CUREVAC NV | 6.1 | 796.20M | ||
| IVA.PA | INVENTIVA SA | N/A | 718.23M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| FYB.DE | FORMYCON AG | N/A | 439.10M |
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 4 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
NFL BIOSCIENCES SA
199 rue Helene Boucher
Castelnau-le-Lez OCCITANIE FR
Employees: 4
Phone: 33411937667
NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. The company is headquartered in Castelnau-Le-Lez, Occitanie and currently employs 4 full-time employees. The company went IPO on 2021-07-05. The firm's products help cure addictions through an approach based on botanical pharmaceutical agents. The company develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. The firm applies scientific approach to other drug candidate with an initial focus targeting the growing addiction to cannabis.
The current stock price of ALNFL.PA is 1.17 EUR. The price increased by 1.92% in the last trading session.
ALNFL.PA does not pay a dividend.
ALNFL.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALNFL.PA.
NFL BIOSCIENCES SA (ALNFL.PA) has a market capitalization of 14.82M EUR. This makes ALNFL.PA a Nano Cap stock.
You can find the ownership structure of NFL BIOSCIENCES SA (ALNFL.PA) on the Ownership tab.
ChartMill assigns a technical rating of 2 / 10 to ALNFL.PA. When comparing the yearly performance of all stocks, ALNFL.PA is a bad performer in the overall market: 93.06% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ALNFL.PA. While ALNFL.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ALNFL.PA reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 54.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.64% | ||
| ROE | -84.25% | ||
| Debt/Equity | 0.01 |
11 analysts have analysed ALNFL.PA and the average price target is 2.99 EUR. This implies a price increase of 155.72% is expected in the next year compared to the current price of 1.17.